Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Yvette Drew

Newcastle AuthorsTitleYearFull text
Dr Yvette Drew
Professor Ruth Plummer
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study2024
Dr Ann Fisher
Dr Yvette Drew
Dr Rachel O'Donnell
Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare Neoplasm2021
Dr Sweta Sharma Saha
Lucy Gentles
Dominik Brecht
Dr Rachel O'Donnell
Professor Nicola Curtin
et al.		Genomic, transcriptomic, and functional alterations in DNA damage response pathways as putative biomarkers of chemotherapy response in ovarian cancer2021
Lucy Gentles
Professor Nicola Curtin
Dr Yvette Drew
Dr Rachel O'Donnell
Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer2021
Alice Bradbury
Dr Rachel O'Donnell
Dr Yvette Drew
Professor Nicola Curtin
Dr Sweta Sharma Saha
Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting2020
Dr Nicola Cresti
Dr Yvette Drew
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor2020
Dr Yvette Drew
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non- BRCA1/2-Mutant Cancers2020
Alice Bradbury
Sally Hall
Professor Nicola Curtin
Dr Yvette Drew
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?2020
Dr Yvette Drew
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer2020
Dr Asima Mukhopadhyay
Dr Yvette Drew
Liz Matheson
Dr Mo Salehan
Lucy Gentles
et al.		Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors2019
Lucy Gentles
Bojidar Goranov
Elizabeth Matheson
Dr Ashleigh Herriott
Dr Angelika Kaufmann
et al.		Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types2019
Professor Nicola Curtin
Dr Yvette Drew
Dr Sweta Sharma Saha
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy2019
Dr Yvette Drew
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in gremlin BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)2018
Lucy Gentles
Liz Matheson
Dr Nicholas Bown
Alice Bradbury
Maryam Zanjirband Zanjirband
et al.		Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor2018
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.		Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
123